| Q43753649 | A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin |
| Q44752312 | Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface |
| Q59234361 | Amino Acids as Co-amorphous Excipients for Simvastatin and Glibenclamide: Physical Properties and Stability |
| Q45811011 | Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement |
| Q46318738 | Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions. |
| Q50258918 | Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ |
| Q52598680 | Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine. |
| Q56980920 | Aspartame as a co-former in co-amorphous systems |
| Q93009153 | Characterising glass transition temperatures and glass dynamics in mesoporous silica-based amorphous drugs |
| Q49092618 | Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying. |
| Q45939827 | Classification of lyophilised mixtures using multivariate analysis of NIR spectra. |
| Q59234583 | Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions |
| Q90715499 | Co-former selection for co-amorphous drug-amino acid formulations |
| Q51542358 | Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. |
| Q38881154 | Correlation between calculated molecular descriptors of excipient amino acids and experimentally observed thermal stability of lysozyme. |
| Q42121711 | Design of experiments-based monitoring of critical quality attributes for the spray-drying process of insulin by NIR spectroscopy |
| Q51523746 | Design space approach in the optimization of the spray-drying process. |
| Q30656382 | Detecting phase separation of freeze-dried binary amorphous systems using pair-wise distribution function and multivariate data analysis. |
| Q89971812 | Determination of the Optimal Molar Ratio in Amino Acid-Based Coamorphous Systems |
| Q46370480 | Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix |
| Q44798428 | Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions |
| Q53034696 | Development of a screening method for co-amorphous formulations of drugs and amino acids. |
| Q93369888 | Dipeptides as co-formers in co-amorphous systems |
| Q61796625 | Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy |
| Q38008517 | Emerging trends in the stabilization of amorphous drugs. |
| Q92406004 | Exploring the chemical space for freeze-drying excipients |
| Q40854029 | Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures. |
| Q45403649 | Formation of mannitol hemihydrate in freeze-dried protein formulations--a design of experiment approach |
| Q44953191 | Fuzzy Logic-based expert system for evaluating cake quality of freeze-dried formulations |
| Q59234221 | Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation |
| Q59233915 | Glass-Transition Temperature of the β-Relaxation as the Major Predictive Parameter for Recrystallization of Neat Amorphous Drugs |
| Q59234011 | Improvement of the physicochemical properties of Co-amorphous naproxen-indomethacin by naproxen-sodium |
| Q42936240 | Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline |
| Q46546738 | In situ amorphisation of indomethacin with Eudragit® E during dissolution |
| Q91037818 | In situ co-amorphisation in coated tablets - The combination of carvedilol with aspartic acid during immersion in an acidic medium |
| Q58552928 | In situ co-amorphisation of arginine with indomethacin or furosemide during immersion in an acidic medium - a proof of concept study |
| Q59233845 | In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine |
| Q92411874 | Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions |
| Q47183480 | Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin |
| Q59233905 | Influence of Solvent Composition on the Performance of Spray-Dried Co-Amorphous Formulations |
| Q50875943 | Influence of preparation pathway on the glass forming ability. |
| Q59233839 | Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids |
| Q50282539 | Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin |
| Q39638481 | Influence of variation in molar ratio on co-amorphous drug-amino acid systems |
| Q59234458 | Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug–polymer mixtures |
| Q50756353 | Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling. |
| Q47712752 | Is there a correlation between the glass forming ability of a drug and its supersaturation propensity? |
| Q39864701 | Large-Scale Biophysical Evaluation of Protein PEGylation Effects: In Vitro Properties of 61 Protein Entities |
| Q40375864 | Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin. |
| Q42278205 | Multivariate analysis of phenol in freeze-dried and spray-dried insulin formulations by NIR and FTIR |
| Q87513138 | Near-infrared imaging for high-throughput screening of moisture induced changes in freeze-dried formulations |
| Q47813276 | On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems |
| Q90443943 | Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems |
| Q47870602 | Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine |
| Q59234161 | Preparation and characterization of spray-dried co-amorphous drug-amino acid salts |
| Q39808123 | Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin |
| Q100424294 | Preparation of Co-Amorphous Systems by Freeze-Drying |
| Q47865775 | Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder. |
| Q61799971 | Process Optimization and Upscaling of Spray-Dried Drug-Amino acid Co-Amorphous Formulations |
| Q59234241 | Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage. |
| Q33806245 | Quality by design approach in the optimization of the spray-drying process. |
| Q83275643 | Rapid solid-state analysis of freeze-dried protein formulations using NIR and Raman spectroscopies |
| Q38710042 | Recent advances in co-amorphous drug formulations |
| Q37579215 | Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. |
| Q38206296 | Refining stability and dissolution rate of amorphous drug formulations |
| Q46121839 | Role of excipients in the quantification of water in lyophilised mixtures using NIR spectroscopy |
| Q48009158 | Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect |
| Q59234265 | Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine |
| Q47718326 | Supersaturating drug delivery systems: The potential of co-amorphous drug formulations. |
| Q89542641 | Surface area, volume and shape descriptors as a novel tool for polymer lead design and discovery |
| Q58198958 | The Influence of Polymers on the Supersaturation Potential of Poor and Good Glass Formers |
| Q59233869 | The Role of Glass Transition Temperatures in Coamorphous Drug–Amino Acid Formulations |
| Q59234647 | The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin |
| Q86410733 | The influence of lysozyme on mannitol polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying process |
| Q47388871 | The significance of the amorphous potential energy landscape for dictating glassy dynamics and driving solid-state crystallisation |
| Q52591642 | The use of molecular descriptors in the development of co-amorphous formulations. |
| Q42923690 | Towards a robust water content determination of freeze-dried samples by near-infrared spectroscopy |
| Q90958210 | Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems |
| Q88399303 | Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions |
| Q38685076 | Unintended and in situ amorphisation of pharmaceuticals. |
| Q88752615 | Using dextran of different molecular weights to achieve faster freeze-drying and improved storage stability of lactate dehydrogenase |
| Q87085684 | Well-plate freeze-drying: a high throughput platform for screening of physical properties of freeze-dried formulations |
| Q90352021 | Whey proteins as stabilizers in amorphous solid dispersions |